Search results
Results from the WOW.Com Content Network
Methylhexanamine (also known as methylhexamine, 1,3-dimethylamylamine, 1,3-DMAA, dimethylamylamine, and DMAA; trade names Forthane and Geranamine) is an indirect sympathomimetic drug invented and developed by Eli Lilly and Company and marketed as an inhaled nasal decongestant from 1948 until it was voluntarily withdrawn from the market in the 1980s.
Nearly 90% of adults over age 20 in the United States are at risk of developing heart disease, an alarming new study suggests.. While the unexpectedly high number doesn't mean that the majority of ...
Compared to ten years ago, fewer adults are using aspirin for the primary prevention of CVD, but the number is still high. The number of adults without CVD who reported using aspirin was 14.4% ...
A recent survey found that while the number of adults using aspirin to prevent heart disease has decreased, about one-third of adults ages 60 and older without heart disease were still taking ...
Human infectious diseases may be characterized by their case fatality rate (CFR), the proportion of people diagnosed with a disease who die from it (cf. mortality rate).It should not be confused with the infection fatality rate (IFR), the estimated proportion of people infected by a disease-causing agent, including asymptomatic and undiagnosed infections, who die from the disease.
The recommended dietary allowance is 15 μg/d (600 IU per day; 800 IU for those over 70 years). Overdose has been observed at 1,925 μg/d (77,000 IU per day). [citation needed] Acute overdose requires between 15,000 μg/d (600,000 IU per day) and 42,000 μg/d (1,680,000 IU per day) over a period of several days to months.
A new study finds that 9 out of 10 adults in the U.S. may have cardiovascular-kidney-metabolic (CKM) syndrome. The research found 90% of adults qualify for stage 1 or higher of this condition.
Dementia impacts not only individuals with dementia, but also their carers and the wider society. Among people aged 60 years and over, dementia is ranked the 9th most burdensome condition according to the 2010 Global Burden of Disease (GBD) estimates. The global costs of dementia was around US$818 billion in 2015, a 35.4% increase from US$604 ...